Form 4: PepGen CEO McArthur Boosts Stake with New Equity Awards

PepGen Inc. President and CEO James G. McArthur was granted 187,688 restricted stock units and 731,250 stock options on March 1, 2026.

Summary

• James G. McArthur, President and CEO of PepGen Inc., acquired 187,688 restricted stock units (RSUs) and 731,250 stock options.
• The RSUs represent the contingent right to receive one share of Common Stock upon vesting, with a transaction price of $0.
• The stock options have an exercise price of $6.22 and were acquired at a transaction price of $0.
• Following these transactions, McArthur beneficially owns 301,601 shares of Common Stock and 731,250 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and expected practice.

Positives

• The grant of restricted stock units and stock options aligns the interests of President and CEO James G. McArthur with those of shareholders.
• The awards incentivize long-term performance and continued service to PepGen Inc.

Negatives

• The future vesting of these awards could lead to a minor dilutive effect on existing shareholders as new shares are issued.

Risks

• The vesting of both RSUs and stock options is subject to James G. McArthur's continued service to PepGen Inc. on each vesting date.

Future Outlook

The equity awards granted to James G. McArthur are structured with multi-year vesting schedules, indicating a long-term commitment to his role and the company's future performance. The RSUs will vest in equal annual installments over four years, with the first installment on March 1, 2027. The stock options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Industry Context

StockSavvy.ai notes that equity compensation, such as restricted stock units and stock options, is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This type of compensation aligns executive interests with long-term shareholder value creation, a critical factor in an industry characterized by lengthy development cycles and significant R&D investment.

Comparison to Industry Standards

• Equity grants of this magnitude for a President and CEO in a biotech company like PepGen Inc. are generally within industry norms for executive compensation packages, particularly for companies in development stages or those with significant growth potential.
• While specific comparable companies are not detailed in the filing, similar structures are observed at peers such as Sarepta Therapeutics or BioMarin Pharmaceutical, where executive compensation often includes substantial equity components tied to performance and tenure.

Stakeholder Impact

• Shareholders: Potential minor dilution over time as RSUs vest and options are exercised, but also increased alignment of executive interests with long-term shareholder value.

Next Steps

• Vesting of 187,688 Restricted Stock Units in equal annual installments over four years, commencing March 1, 2027.
• Vesting of 731,250 Stock Options, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments thereafter.

Key Dates

Keywords

PepGen Inc., PEPG, James G. McArthur, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Awards